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Abstract
Background: Intake of large neutral amino acids (LNAA) may inhibit phenylala-
nine (PHE) transport across the blood brain barrier and assist with blood PHE con-
trol in patients with phenylketonuria (PKU). We evaluated the interrelationship
between LNAA in plasma and diet on Phe:Tyr (P:T) ratio in patients with PKU
and the influence of dietary factors on plasma LNAA markers.
Methods: Plasma amino acid values and 3-day food record analysis from two stud-
ies (34 male/30 female; age 4.6-47 years) were examined. For pediatrics (<18 years)
and adults (≥18 years) the relationship between P:T ratio, plasma LNAA, and dietary
intake patterns were investigated.
Results: Dietary factors influencing P:T ratio included intake of total protein
(g/kg), medical food (MF) protein (g/kg, % below Rx), and LNAA (g) in the full
cohort (P < .05). Associations were found between plasma valine and other dietary
and plasma LNAA in pediatrics (P < .05) and plasma LNAA with dietary LNAA
intake in adults (P = .019). Plasma P:T ratio was inversely associated with plasma
LNAA concentrations in both age groups (P < .05). Aside from histidine in pediat-
rics (P = .024), plasma LNAA did not differ by having plasma PHE levels within
or above the therapeutic range (120-360 μmol/L). Plasma LNAA in both age
groups was similar to reported healthy control values.
Conclusion: P:T ratio is significantly tied to dietary LNAA, adherence to MF Rx,
and plasma LNAA concentrations. Additionally, P:T ratio and valine may be effec-
tive clinical proxies for determining LNAA metabolic balance and LNAA quality
of the diet in patients with PKU.
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1 | INTRODUCTION
Phenylketonuria (PKU) is an autosomal recessive genetic
disorder in which the enzyme, phenylalanine hydroxylase
(PAH), produced in the liver, is deficient. The reduced
activity of PAH causes phenylalanine (PHE) to build up in
the blood and body tissues which is toxic to the central ner-
vous system, most notably the brain.1 PKU is traditionally
treated with a medical diet consisting of strict low amounts
of dietary PHE and a synthetic, PHE free, amino acid-based
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nutritional formula (medical food) that serves as the major
dietary protein source.1,2 The goal of the diet is to keep
plasma blood PHE within the therapeutic range of
120-360 μmol/L, the level needed for normal development
and cognitive function across all ages.
Plasma concentration of large neutral amino acids
(LNAA) may also play an important role in the treatment of
PKU, particularly with the presence of LNAA in prescrip-
tion medical foods and with prescribed LNAA supplements
becoming more prevalent as a treatment option.3,4 Large
neutral amino acids include the essential amino acids histi-
dine, isoleucine, leucine, methionine, threonine, tryptophan,
phenylalanine, and valine as well as the nonessential amino
acid tyrosine. Consumption of supraphysiologic LNAA sup-
plements as a part of treatment in PKU may increase blood
LNAA levels and reduce PHE concentrations in the blood
and brain.5,6 However, significance in PHE reduction only
occurred in the absence of medical food. This highlights the
importance of amino acid rich medical food in PHE control.
Several studies have found clear associations between PHE
control in PKU and medical food compliance, dosing, and
amino acid content.7-10 However, investigation of medical
food LNAA content on P:T ratio is not represented in the lit-
erature. As long term P:T ratio has been found to associate
with executive functioning, anxiety, and depression risk out-
comes in PKU,11,12 it is of clinical importance to determine
the role of dietary LNAA from medical food and intact food
sources on P:T ratio.
Mechanism of action regarding LNAA influence on met-
abolic control in PKU and brain function most likely
involves competitive uptake inhibition in the gut and across
the blood brain barrier (BBB).13,14 L-type amino acid trans-
porter 1 (LAT1) is a common transport system for PHE and
other LNAA across cellular membrane barriers, including
the BBB.5 Higher concentrations of LNAA may inhibit
excess PHE uptake at LAT1 sites.15 Supportive mouse stud-
ies demonstrate that LNAA substantially decrease brain
PHE, reduce LNAA brain deficiencies, and lead to improved
monoamine neurotransmitter status.14-16 However, as with
LNAA and P:T ratio, the association between LNAA intake
among patients with PKU on plasma LNAA concentrations
has not been well-established. Given the potential interaction
that plasma LNAA and P:T ratio may have, this is important
to know.
Therefore, the purpose of this study is to examine the
effect LNAA intake from medical food and intact protein
have on both P:T ratio and plasma LNAA in children and
adults with PKU. These data are useful for determining
intervention for optimizing LNAA status and P:T ratio in
patients with PKU so as to improve clinical outcomes.
2 | MATERIALS AND METHODS
2.1 | Study population
The study sample (detailed in Figure 1) includes age diverse
male and female participants from two previous studies by
Emory University School of Medicine, Department of
Human Genetics. Methods for these studies have been previ-
ously described in the peer-reviewed literature.17,18 For this
analysis, the sample consisted of adolescent and adult
females, within and outside of Georgia, who attended the
Emory Metabolic Camp in the summer of 2016. Added to
this sample was males and females 4 years of age and older
from 2009 baseline data of PKU patients thereafter intro-
duced to sapropterin (Kuvan, Biomarin, Inc.). Age appropri-
ate informed consent and assent procedures were followed
in all circumstances. All patients had been diagnosed with
PKU through the Newborn Screening Protocol. If a study
subject was present in both camp and sapropterin data sets,
the subject was deleted from the older baseline sapropterin
set and retained in the 2016 camp data set for analysis. One
exception was a subject on sapropterin in the camp data set
and thus retained in the 2009 baseline data set. Exclusion
criteria were non-PKU individuals, pregnant and nursing
females, patients under the age of 4 years, those taking either
a tyrosine or LNAA supplement, those receiving pharmaco-
logic treatments for their PKU (Kuvan and PEGPAL) at time
Kuvan study, N=55
No exclusions
Final Kuvan sample
n=55
2016 camp, N=22
-8: On Kuvan
-3: On PegPal
-2: On LNAA supplement
Final camp sample
n=9
Final Sample 
N=64
FIGURE 1 Flow chart of baseline study sample [Color figure can
be viewed at wileyonlinelibrary.com]
SYNOPSIS
Dietary factors play a role in LNAA plasma concen-
trations for the potential benefit of PHE control in
the blood and across the blood brain barrier, while
plasma valine and P:T ratio may serve as effective
biomarkers of overall LNAA status.
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of data collection, and patients with cognitive deficits affect-
ing ability to provide informed consent or follow study
instructions.
2.2 | Study design
This is a secondary retrospective cohort study. Deidentified
data previously collected as part of the Institutional Review
Board (IRB) approved Emory Metabolic Camp and
sapropterin study protocols were used as described in the
prior section. Each patient was assigned a random study
identification number. Variables included demographic char-
acteristics (age in years, gender, and race), anthropometrics
(weight, height, calculated BMI), nutrient intake from die-
tary food records, plasma amino acids, and determinants of
dietary compliance. Ethics approval for this secondary retro-
spective study was received from the Georgia State Univer-
sity IRB and met Emory University IRB standards.
2.3 | Anthropometric and dietary measures
Weight in kilograms (kg) was measured with a standing
scale. Height in centimeters (cm) was determined using a
stadiometer. Body mass index (BMI) was calculated [weight
(kg) / height (meters)2]. Subjects under 18 years have BMI
reported as a percentile. All measures were conducted by
trained research staff. Participants at the Emory Metabolic
Camp and at the baseline visit for the sapropterin study com-
pleted a 3-day food record prior to their visit. A registered
dietitian (RD) from Emory University analyzed collected
food records for nutrient intake using Nutrition Data System
for Research (NDSR; Nutrition Coordinating Center, Uni-
versity of Minnesota, 2016). Participants were determined to
be adherent with their PKU diet if blood PHE levels were
within recommended range (120-360 μmol/L).19 To deter-
mine adherence to prescribed medical food (MF), reported
intake was subtracted from prescribed and converted to the
percent intake below prescription (Rx). For adherence to die-
tary PHE, prescribed dietary PHE was subtracted from
reported PHE intake and converted to percent intake
above Rx.
2.4 | Blood sampling
Green top sodium heparin vacutainers were used for blood
sampling. Plasma amino acids were analyzed using quantita-
tive ion exchange chromatography at the Emory Genetics
Laboratory. Plasma LNAA reported, aside from PHE and
Tyr, included valine, leucine, isoleucine, methionine, threo-
nine, and histidine. For a subcohort in the study (n = 50)
tryptophan was also reported. Sum plasma LNAA was cal-
culated by adding the individual plasma LNAA
concentrations, a method previously utilized in the litera-
ture.20 Plasma tryptophan for the sum LNAA was not
included in the complete cohort analysis but was calculated
in for the subcohort. The same approach was taken for die-
tary tryptophan when determining sum LNAA in the diet. In
the case of sum LNAA associations with P:T ratio, tyrosine
was removed from the sum to reduce confounding. Plasma
PHE was excluded from sums to prevent confounding by
high PHE levels, and as PHE control was already being
evaluated.
2.5 | Statistical analysis
Frequency analysis was used to describe demographic,
anthropometric, nutrient intake, and clinical characteristics
of the combined sample. Normality testing was conducted
on all continuous variables to determine whether parametric
or nonparametric statistics should be used. Correlations were
used to identify potential cofactors such as age, gender, and
dietary compliance. To control for possible age related dif-
ferences relevant to dietary and metabolic parameters, the
sample was divided into pediatrics (<18 years) and adults
(≥18 years). Kendall's tau and multivariate regression were
used to assess relationships between plasma LNAA, plasma
P:T ratio, LNAA intake from diet sources and in association
with adherence to MF Rx. The t test comparisons were used
to detect potential group differences between sum (plasma
and intake) LNAA values with and without tryptophan.
Compliance status of the study sample was determined by
plasma PHE concentrations. Those with plasma PHE
exceeding 360 μmol/L were categorized as “noncompliant”
with their PKU treatment plan independent of reported
intakes on their diet record Differences based on PKU diet
compliance were investigated with Mann-Whitney U test or
t test. Margins of error are reported as 25th and 75th percen-
tiles or SD dependent on normality of the data. Multiple
comparisons due to separation of sample by age group were
Bonferroni adjusted. All statistical analyses were performed
with SPSS (version 24.0, SPSS Inc. Chicago, IL). IBM
SPSS Sample Power (version 3) was used to assess needed
sample size for a regression model with up to three variables
at a power of 0.80. Alpha was set at 0.05.
3 | RESULTS
3.1 | Demographic, anthropometric,
and nutrient intake characteristics
The final cohort included 64 participants (53% male) with
an age range of 4.6-47 years. The majority of participants
were in the sapropterin study (n = 55) while the remaining
(n = 9) attended the Emory Metabolic Camp in the
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summer of 2016 (Figure 1). Total study power based on
sample size achieved is 0.99, with a minimum of
29 needed for a power of 0.80. The demographic, anthropo-
metric, and prescribed diet adherence characteristics of the
study group are shown in Table 1. Mean (±SD) per kilogram
protein intake for the complete study group was 1.30 g/kg
(±0.64). After subdivision by protein source, whole group
mean (±SD) dietary intact protein intake was 0.41 (±0.32)
g/kg and 0.89 (± 0.62) g/kg for MF protein intake. Of the
61 participants on MF, one was prescribed a glyco-
macropeptide (GMP) product, while the others were on a
PHE-free synthetic amino acid MF. Among those on pre-
scribed MF, 43 (70%) reported consuming full prescribed
amount. The median percent dietary protein from MF in the
full cohort was 73.9% (IQR; 51.8, 84.1). Of 59 participants
with reported dietary PHE restriction, 81% (n = 52) had intake
at least 5%, above recommended, with 43 subjects exceeding
PHE intake recommendation by more than 20%. Per expecta-
tions, nonadherence to dietary PHE restriction was greater in
adults, with median PHE intake 61.3% above recommended.
In pediatrics, median excess PHE intake was 26.3% above
recommended.
Comparisons of dietary sum LNAA (g) with and with-
out tryptophan, and plasma sum LNAA (μmol/L) with and
without tryptophan yielded no significant differences
(P = .54, P = .14; respectively), validating outcomes in the
subcohort in which plasma tryptophan concentrations were
included.
3.2 | Dietary factors affecting plasma
P:T ratio
In the separate age groups, dietary LNAA (g) were not
associated with P:T ratio. For pediatrics, intake of protein
(g, g/kg), energy (kcal, kcal/kg), and ratio of MF to intact
protein were also not associated with plasma P:T ratio. In
adults, g/kg intake of total protein and MF protein were each
inversely correlated with P:T ratio (τ = −0.442, P = .001)
(τ = −0.337, P = .014), emphasizing the importance of die-
tary adherence on metabolic control. Moreover, the percent-
age of MF protein the patient consumed below their
prescription had a direct correlation with P:T ratio (τ = 0.307,
P = .029), though not after Bonferroni correction.
Within the full cohort, when controlled for linear age, P:
T ratio was inversely associated with dietary intake (g) of
the LNAA sum (Figure 2A), and with intake of specific
LNAA (P ≤ .048) other than threonine (r = −0.224,
P = .054), tryptophan (r = −0.241, P = .057), and PHE
(r = −0.004, P = .978). The full cohort, as with the adult
subcohort, also demonstrated strong association of P:T ratio
with MF intake (g/kg, % below Rx) (r = −0.273 P = .030;
r = 0.433 P < .001) and total protein intake (g, g/kg)
(r = −0.273 P = .031; r = −0.337 P = .007).
3.3 | Dietary factors affecting plasma LNAA
Evaluating correlations between individual dietary LNAA
intake (g) and plasma LNAA levels, significant positive asso-
ciations were found in the full cohort with the sum LNAA
values (Figure 2B) and in the pediatric subcohort with isoleu-
cine (τ = 0.25, P = .029) and valine (τ = 0.35, P = .003). In
adults, positive associations were found with valine (τ = 0.29,
P = .033) and with sum LNAA, (τ = 0.39, P = .019). Dietary
tyr correlated with plasma valine for both pediatrics
(τ = 0.319, P = .006) and adults (τ = 0.274, P = .045) along
with sum plasma LNAA (P ≤ .044). Dietary tyr for pediatrics
also correlated with plasma isoleucine (τ = 0.245, P = .035)
and tryp (τ = 0.276, P = .027). Once Bonferroni corrected,
the only significant correlations were with valine in the pedi-
atric group, and between dietary sum LNAA and plasma sum
LNAA (with tryptophan) in the adults.
Of note, in the pediatric cohort, plasma valine had
strong positive correlation with intake of all dietary LNAA
(P ≤ .015) excepting PHE and tryptophan, and with plasma
LNAA (P ≤ .019), excepting PHE. In adults, valine like-
wise directly associated with the plasma BCAA (P ≤ .002),
threonine (τ = 0.284, P = .039), and the sum plasma
LNAA (τ = 0.0742, P < .001). Only dietary threonine
(g) (τ = 0.331, P = .016) and tryptophan (g) (τ = 0.342,
P = .012) intakes correlated with plasma valine in adults
once Bonferroni corrected.
TABLE 1 Baseline characteristics of the study cohort
Characteristic N = 64 Mean ± SD
Gender, n
Male: n = 34
Female n = 30
Age group (n)a Pediatric (n = 37) 10.4 ± 4.2
Adult (n = 27) 27.9 ± 8.6
BMI, percentile Pediatric 60.2 ± 29.7
BMI (kg/m2) Adults 30.7 ± 8.3
n (%)
Phe intake above recommended
(out of n = 59)a
Pediatric (n = 34) 27 (79.4%)
Adults (n = 25) 20 (80.0%)
MF intake below Rx (n = 64) Pediatric (n = 37) 10 (27.0%)
Adults (n = 27) 10 (48.0%)
Note. Pediatric: <18 years of age. Adults: ≥18 years of age.
Abbreviations: BMI, body mass index; MF, medical food; Phe, phenylalanine;
Rx, prescription; SD, standard deviation.
aFor three subjects, medically recommended Phe intake was not available due to
length of time off diet. Two subjects had mild hyperphe and thus not Phe
restricted.
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Plasma histidine correlated with MF protein (g) intake in
pediatrics (τ = 0.33, P = .004) and total protein intake
(g/kg) in adults (τ = 0.39, P = .005). Histidine associations
held after Bonferroni correction. No significant correlations
were found between plasma LNAA and intake measures of
dietary PHE (Figure 2C), medical food protein, intact pro-
tein, total protein, or sex in either age group. Comparison
of LNAA markers by compliance status (as determined by
plasma PHE above or below 360 μmol/L) across age
groups were not statistically significant, with exception of
significantly higher plasma histidine (P = .024, Bonferroni
adjusted) in dietary compliant vs noncompliant pediatrics
(mean ± SD: 80.7 ± 13.4 vs 69.0 ± 12.6 μmol/L).
Even so, histidine intake (g/day) was similar across both
pediatric compliance groups (medians: 1.36 vs 1.46 g/d;
P = 0.376).
3.4 | LNAA interaction with plasma PHE, tyr,
and P:T ratio
In the full cohort controlled for age, plasma PHE associated
inversely with the sum plasma LNAA (Figure 2D), and with
individual LNAA results (P ≤ .027) except for valine, isoleu-
cine, and leucine which were not statistically significant.
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Plasma tyr had significant positive associations with LNAA
outcomes (P ≤ .028) other than plasma methionine
(r = 0.246, P = .052) and histidine (r = 0.241, P = .058).
Median plasma P:T values for adults was 16.2 (IQR: 8.9,
34.0) and 9.8 (IQR: 5.5, 20.3) for pediatrics. For both pediat-
ric and adult groups with PKU, plasma P:T ratio had signifi-
cant inverse associations with plasma threonine, histidine, and
sum plasma LNAA (tyr removed) (Table 2). When evaluating
the full cohort with Kendall's tau, P:T ratio had significant
inverse correlations with all plasma LNAA concentrations
(P ≤ .028) except for isoleucine (τ = −0.166, P = .056).
When, controlling for linear age, isoleucine was also inversely
correlated with P:T ratio (r = −0.334, P = .007).
3.5 | Plasma LNAA and LNAA intake
compared to general population
There is no general population standard, or matched non-
PKU cohort, to compare against the mean plasma LNAA
concentrations in our study group. Nevertheless, a study
conducted by Scriver et al22 examined plasma amino acid
levels in healthy adults and another published by Lepage
et al21 reported proper methods of obtaining plasma amino
acid levels in a healthy pediatric population. Based on these
two studies, our cohort had plasma levels of LNAA compa-
rable to that observed in healthy children and adults, with
the exception of PHE (Table 3A,B).
4 | DISCUSSION
This study adds to the research literature on LNAA and their
role in managing the metabolic needs of those with PKU. As
nutritional and pharmacologic therapies for PKU change,
dietary patterns do as well, which can affect health outcomes
in diverse ways. The general literature consensus is that
LNAA supplementation or specific MF higher in LNAA
could benefit patients with PKU, even more so combined
with metabolic PHE control. Particularly worth noting are
the LNAA supplements available now for PKU patients to
be taken in addition to or as a replacement for traditional
MF.22,25 One study investigated the combination of
sapropterin with LNAA supplementation, revealing a syner-
gistic effect on serum melatonin in BH4 responders.26
Our study focused on plasma LNAA and LNAA intake
within the limits of PKU dietary adherence. Interestingly, we
found in our study an inverse association of P:T ratio with
multiple LNAA and the sum of LNAA in plasma (Table 2)
even though compliance status as determined by plasma PHE
levels was minimal in its effect on LNAA. Therefore, poor
maintenance of plasma P:T ratio may be of greater relevance
to LNAA balance than plasma PHE alone, potentially attenuat-
ing the benefits of increased dietary LNAA. That LNAA other
than PHE in the diet had a greater influence on both P:T ratio
and LNAA concentrations suggests competitive transport
between PHE and the LNAA at the gut level. Thus, greater
LNAA in the diet, though not a substitute for PHE control, are
effective when combined with a holistic approach to PKU
treatment that promotes the right balance of P:T in the blood.
Although human research into the effects of LNAA intake
on brain PHE is limited, one study observed a lowering of
brain PHE levels with increased LNAA intake, as measured
by Magnetic Resonance Spectroscopy. This occurred despite
no observed increase in plasma LNAA concentrations.5
Schindeler et al reported blood isoleucine, threonine, tyrosine,
valine, lysine, and histidine levels to be higher when subjects
TABLE 2 Associationa of P:T ratio with individual and sum plasma LNAA (excluding tyrosine)
Plasma outcome marker(μmol/L) Pediatrics (τ)b(n = 37) Adults (τ)b(n = 27) Complete samplec(τ) (n = 64)
Histidine –0.336** –0.345* –0.295**
Isoleucine –0.240 –0.196 –0.166
Leucine –0.220 –0.233 –0.189*
Methionine –0.194 –0.251 –0.258**
Threonine –0.281* –0.475** –0.344**
Tryptophan –0.254 (n = 32) –0.251 (n = 18) –0.285** (n = 50)
Valine –0.215 –0.291 –0.225*
Sum LNAA (w/o tryp and tyr) –0.293* –0.459** –0.559**
Sum LNAA (w/o tyr) (n = 50) –0.299* (n = 32) –0.345 (n = 18) –0.527** (n = 50)
Abbreviation: LNAA, large neutral amino acids.
*P < .05.
**P < .01.
aKendall-tau.
bBonferroni adjusted for separate age groups.
cSignificant associations of complete cohort confirmed with multivariate regression adjusting for linear age.
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received LNAAs in their MF mixtures, although neither data
nor level of significance for the reported relationship was pro-
vided in their manuscript. Our results, although showing a
clear association between dietary LNAA intake and sum
plasma LNAA, when we evaluated distinct LNAA, valine par-
ticularly stood out. The noted association of valine with both
plasma and dietary LNAA, as well as P:T ratio, indicates
valine may be an important marker of LNAA status, dietary
adherence, and metabolic control in patients with PKU. Hence,
there is potential for valine's clinical application as a proxy of
LNAA balance in pediatrics with PKU, perhaps in
combination with P:T ratio. Why specifically valine was sig-
nificant as opposed to other LNAAs is unclear. However,
given the role of valine in PHE access across the blood brain
barrier, this finding is of importance. The limited associations
between dietary LNAA and plasma concentrations may be due
to homeostatic mechanisms as the amino acids are taken up by
cells to be used and metabolized for functional purposes. For
example, a clinical study found that threonine catabolism via
oxidation increases during dietary threonine supplementation
as either free amino acids or from intact protein,27 although
increases in plasma threonine were still observed. A similar
TABLE 3 P:T and LNAA intake and plasma values (μmol/L) in PKU cohort compared to published values for healthy pediatric (A) and
healthy adult (B) groups
LNAA N
Intake (mg/day)
Median, IQR
Plasma (μmol/L)
Mean, SD
Lepage et al 1997a
(μmol/L)21 Median
Plasma RRb
(μmol/L)
P:T 37 NA 13.62 ± 11.51 - -
Phenylalanine 37 473 (303,779) 551 ± 298 49,57 26-91
Tyrosine 37 4239 (3424,5666) 52 ± 19 55,65 24-115
Tryptophan 37/31 667 (524,841) 46 ± 14 56,74 -
Threonine 37 2364 (2000,2878) 108 ± 31 94,131 35-226
Isoleucine 37 3094 (2616,4107) 50 ± 14 54,60 22-107
Leucine 37 5377 (4490,6527) 101 ± 28 110,128 49-216
Methionine 37 1106 (887,1305) 22 ± 5 20,26 7-47
Valine 37 3600 (3060,4677) 206 ± 55 199,233 74-321
Histidine 37 1451 (1167,1678) 73 ± 14 78,92 41-125
Sum LNAA (without Tryptophan) 37 21 218 (18000,26365) 611 ± 126 - -
Sum LNAA (with tryptophan) 37/31 22051 (18543,27102) 661 ± 138 - -
LNAA N Intake (mg/day)
Median, IQR
Plasma (μmol/L)
Mean, SD
Scriver et al 1985c
(μmol/L)20Mean
Plasma RRb
(μmol/L)
P:T 27 NA 20.6 ± 13.5 - -
Phenylalanine 27 997 (484,2030) 929 ± 467 58 49-76
Tyrosine 27 4771 (2745,7043) 52 ± 20 64 41-78
Tryptophan 27/17 1027 (715,1595) 40 ± 14 - -
Threonine 27 3005 (2446,4054) 117 ± 57 145 85-186
Isoleucine 27 3300 (2690,4521) 51 ± 12 64 40-83
Leucine 27 6255 (4626,8107) 107 ± 26 133 88-158
Methionine 27 1474 (1162,1614) 20 ± 4 24 21-41
Valine 27 4565 (3283,5370) 218 ± 79 264 164-275
Histidine 27 1896 (1586,2548) 75 ± 15 94 52-128
Sum LNAA (without Tryptophan) 27 26125 (19536,33716) 639 ± 166 - -
Sum LNAA (w tryptophan) 27/17 26840 (20324,35355) 692 ± 178 - -
Abbreviations: IQR, interquartile range; LNAA, large neutral amino acids; NA, not applicable; P:T, Phenylalanine:Tyrosine ratio; SD, standard deviation; mg,
milligrams; μmol, micromoles; L, liter.
aHealthy pediatric controls. Reported medians for 6 years and 16 years, respectively. Dietary data not collected by authors.
bHealthy population reference range (RR) as reported by Emory Genetics Laboratory.
cHealthy adult controls. Dietary data not collected by authors.
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effect may explain the increase in plasma valine seen with
higher valine in the diet. However, clinical measures of down-
stream LNAA metabolites (ie, respective keto-acids, histamine
from histidine, cysteine from methionine) in patients with
PKU, combined with dietary intake and plasma concentra-
tions, are needed to identify the mechanisms that maintain sta-
ble LNAA plasma levels relevant to diet patterns.28
Additionally, measuring flux across membrane barriers for cel-
lular uptake could add further insight, particularly as studies
have shown that prescribing LNAA supplements to patients
with PKU may be an effective therapy3,15,29 due to competi-
tive inhibition of PHE across both the gut and blood brain
barriers.
Rohde et al30 examined LNAA status along with other
nutrients in a PKU patient sample similar to our own study
sample by evaluating the total protein intake in those who
consumed medical food vs those who did not. The researchers
found no significant difference in the total protein intake and
no deficit in one LNAA intake, which is consistent with our
overall findings. As expected, many participants in our study
exceeded recommended intake of PHE and underconsumed
their medical food compared to their Rx (Table 1).
Within our study, dietary influence regarding protein source,
MF or intact protein and dietary compliance status as measured
by plasma PHE, had little bearing on plasma LNAA concentra-
tions, although extent of noncompliance as determined by
plasma PHE was a factor in lower plasma histidine concentra-
tions among pediatrics. Even so, most still fell within the clini-
cal reference range of 50-104 μmol/L (LabCorp) for histidine.
There are limitations within the current study. The major-
ity of participants (75%) were noncompliant as evidenced by
plasma PHE levels >360 μmol/L, which reduced the size of
the compliant subgroup for our analysis. Unfortunately, high
numbers of noncompliance with plasma PHE and diet
requirements, particularly among adolescents and adults, are
common in the PKU medical population.31-34 Another limi-
tation was that plasma tryptophan could not be calculated
into the sum of plasma LNAA concentrations in 14 cases.
This may have affected the sum of the plasma LNAA con-
centration values and the significance of associations in the
analysis. However, subgroup analysis among participants
with plasma tryptophan available was completed, and results
were similar to the full analysis that excluded tryptophan.
5 | CONCLUSION
Our research has demonstrated a clear inverse relationship
between LNAA concentrations in the plasma and P:T ratio,
with dietary and plasma tyrosine of greater weight than PHE.
We also found that P:T ratio correlated with dietary intake of
total protein, MF protein, and LNAA (in the full cohort,
Figure 2A). In addition, associations were discovered with
plasma valine when correlated with other plasma LNAA, die-
tary LNAA intake, in conjunction with P:T ratio. This strength
of association valine had with multiple dietary and plasma
markers was distinct among the other LNAA. The results sup-
port the premise that both P:T ratio and valine may be clini-
cally valuable predictors and potential mediators of LNAA
balance among individuals with PKU. More studies are
needed to best apply LNAA nutrition either within the PKU
standard diet or as supplemental therapy, while optimizing P:T
balance and long-term health in PKU. Such research would
investigate specific mechanisms of interaction between diet,
LNAA plasma concentrations, P:T ratio and downstream
metabolism and utilization of LNAA, as well as the efficacy of
valine and P:T ratio in predicting LNAA balance in PKU.
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